Zhengxiao L, Fanpu J, Yan Z, Jingang A, Zhenhui P

Idioma: Ingles.
Referencias bibliográficas: 6
Paginas: 570-571
Archivo PDF: 83.83 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.

2. Edwards IR, Aronson JK. Adverse drugs reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.

3. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 2002; 147: 1142-6.

4. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment associated dermatitis in 36 prospective cases. Br J Dermatol 2005; 153: 1088-90.

5. Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol 2007; 34: 577-82.

6. Veldt BJ, Schalm SW, Janssen HL. Severe allergic eczema due to pegylated alfa interferon may abate after switching to daily conventional alfa-interferon. J Clin Gastroenterol 2007; 41: 432.